Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) EBIT Margin (2023 - 2026)

Krystal Biotech's EBIT Margin history spans 4 years, with the latest figure at 46.14% for Q1 2026.

  • On a quarterly basis, EBIT Margin rose 503.0% to 46.14% in Q1 2026 year-over-year; TTM through Mar 2026 was 42.81%, a 1022.0% increase, with the full-year FY2025 number at 41.45%, up 1882.0% from a year prior.
  • EBIT Margin hit 46.14% in Q1 2026 for Krystal Biotech, up from 41.34% in the prior quarter.
  • Over the last five years, EBIT Margin for KRYS hit a ceiling of 46.14% in Q1 2026 and a floor of 303.8% in Q3 2023.
  • Historically, EBIT Margin has averaged 1.33% across 4 years, with a median of 40.94% in 2025.
  • Biggest five-year swings in EBIT Margin: skyrocketed 33060bps in 2024 and later plummeted -407bps in 2025.
  • Tracing KRYS's EBIT Margin over 4 years: stood at 7.71% in 2023, then surged by 489bps to 45.41% in 2024, then dropped by -9bps to 41.34% in 2025, then rose by 12bps to 46.14% in 2026.
  • Business Quant data shows EBIT Margin for KRYS at 46.14% in Q1 2026, 41.34% in Q4 2025, and 42.3% in Q3 2025.